Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals will participate in four upcoming investor conferences, including the H.C. Wainwright 4th Annual BioConnect Conference, Stifel 2026 Virtual Oncology Forum, TD Cowen 6th Annual Oncology Innovation Summit, and Jefferies Global Healthcare Conference. The management team will engage in fireside discussions at each event, providing updates on the company's development of azenosertib, a first-in-class WEE1 inhibitor for ovarian cancer and other tumor types.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.